Upregulation of chemokines and their receptors in duchenne muscular dystrophy: Potential for attenuation of myofiber necrosis

Muscle and Nerve

Volumn 46, Issue 6, 2012, Pages 914-916

  De Paepe, Boel ^a   Creus, Kim K ^a   Martin, Jean Jacques ^b   De Bleecker, Jan L ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Chemokine receptors; Chemokines; Duchenne muscular dystrophy; Muscle regeneration; Myositis

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; DYSTROPHIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1 INHIBITOR; RANTES; STROMAL CELL DERIVED FACTOR 1; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ARTICLE; BLOOD VESSEL; CELL DEATH; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MACROPHAGE; MUSCLE BIOPSY; MUSCLE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCHOOL CHILD; TISSUE REGENERATION;

EID: 84870178868     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23481     Document Type: Article

References (31)

1. Deconinck N, Dan B. Pathophysiology of Duchenne muscular dystrophy: current hypotheses. Pediatr Neurol 2007; 36: 1-7.
2. Petrof BJ. Molecular pathophysiology of myofiber injury in deficiencies of the dystrophin-glycoprotein complex. Am J Phys Med Rehabil 2001; 81( suppl): S162-174.
3. McDouall RM, Dunn MJ, Dubowitz V. Nature of the mononuclear infiltrate and the mechanism of muscle damage in juvenile dermatomyositis and Duchenne muscular dystrophy. J Neurol Sci 1990; 99: 199-217.
4. Locati M, Murphy PM. Chemokines and chemokine receptors: biology and clinical relevance in inflammation and AIDS. Annu Rev Med 1999; 50: 425-440.
5. Porter JD, Guo W, Merriam AP, Khanna S, Cheng G, Zhou X, et al. Persistent overexpression of specific CC class chemokines correlates with macrophage and T-cell recruitment in mdx skeletal muscle. Neuromuscul Disord 2003; 13: 223-235.
6. Demoule A, Divangahi M, Danialou G, Gvozdic D, Larkin G, Bao W, et al. Expression and regulation of CC class chemokines in the dystrophic (mdx) diaphragm. Am J Respir Cell Mol Biol 2005; 33: 178-185.
7. Pescatori M, Broccolini A, Minetti C, Bertini E, Bruno C, D'Amico A, et al. Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. FASEB J 2007; 21: 1210-1226.
8. Hogaboam CM, Bone-Larson CL, Steinhauser ML, Lukacs NW, Colletti LM, Simpson KJ, et al. Novel CXCR2-dependent liver regenerative qualities of ERL-containing CXC chemokines. FASEB J 1999; 13: 1565-1574.
9. Omari KM, John G, Lango R, Raine CS. Role for CXCR2 and CXCL1 on glia in multiple sclerosis. Glia 2006; 53: 24-31.
10. Nedachi T, Hatakeyama H, Kono T, Sato M, Kanzaki M. Characterization of contraction-inducible CXC chemokines and their roles in C2C12 myocytes. Am J Physiol Endocrinol Metab 2009; 297: E866-E878.
11. Griffin CA, Apponi LH, Long KK, Pavlath GK. Chemokine expression and control of muscle cell migration during myogenesis. J Cell Sci 2010; 123: 3052-3060.
12. Melchionna R, Romani M, Ambrosino V, D'Arcangelo D, Cencioni C, Porcelli D, et al. Role of HIF-1 alpha in proton-mediated CXCR4 down-regulation in endothelial cells. Cardiovasc Res 2010; 86: 293-301.
13. Ratajczak MZ, Majka M, Kucia M, Drukala J, Pietrzkowki Z, Peiper S, et al. Expression of functional CXCR4 by muscle satellite cells and secretion of SDF1 by muscle-derived fibroblasts is associated with the presence of both muscle progenitors in bone marrow and hematopoietic stem/progenitor cells in muscle. Stem Cells 2003; 21: 363-371.
14. Abdel-Salam E, Abdel-Meguid E, Shatlah R, Korraa SS. Stromal cell-derived factors in Duchenne muscular dystrophy. Acta Myol 2010; 29: 396-403.
15. Bleul CC, Frazan M, Cloe H, Parolin C, Clark-Lewis I, Sodroski J, et al. The lymphocyte chemoattactant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996; 382: 829-833.
16. Yahiaoui L, Gvozdic D, Danialou G, Mack M, Petrof BJ. CC family chemokines directly regulate myoblast responses to skeletal muscle injury. J Physiol 2008; 586: 3991-4004.
17. Warren GL, Hulderman T, Mishra D, Gao X, Millecchia L, O'Farrell L, et al. Chemokine receptor CCR2 involvement in skeletal muscle regeneration. FASEB J 2004; 18: 413-435.
18. Middleton J, Patterson AM, Gardner L, Schmutz C, Ashton BA. Leukocyte extravasation: chemokine transport and presentation of the endothelium. Blood 2002; 100: 3853-3860.
19. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine systems in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677-686.
20. Arnold L, Henry A, Paro, F, Baba-Amer Y, van Rooijen N, Planquet A, et al. Inflammatory monocytes recruited after skeletal muscle injury switch into anti-inflammatory macrophages to support myogenesis. J Exp Med 2007; 204: 1057-1069.
21. Louvet A, Teixeira-Clerc F, Chobert MN, Deveaux V, Pavoine C, Zimmer A, et al. Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology 2001; 54: 1217-1226.
22. Villalta SA, Nguyen HX, Deng B, Gotoh T, Tidball JG. Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum Mol Genet 2009; 18: 482-496.
23. Hussein MR, Hamed SA, Mostafa MG, Abu-Dief EE, Kamel NF, Kandil MR. The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies. Int J Exp Pathol 2006; 87: 451-461.
24. De Paepe B, Creus KK, De Bleecker JL. Chemokines in idiopathic inflammatory myopathies. Front Biosci 2008; 13: 2548-2557.
25. van Putten M, Aartsma-Rus A. Opportunities and challenges for the development of antisense treatment in neuromuscular disorders. Expert Opin Biol Ther 2011; 11: 1025-1037.
26. Wong BLY, Christopher C. Corticosteroids and Duchenne muscular dystrophy: a reappraisal. J Child Neurol 2002; 17: 183-190.
27. Porreca E, Guglielmi MD, Uncini A, Di Gregorio P, Angelini A, Di Febbo C, et al. Haemostatic abnormalities, cardiac involvement and serum tumor necrosis factor levels in X-linked dystrophic patients. Thromb Haemost 1999; 81: 543-546.
28. Grounds MD, Torrisi J. Anti-TNFα (Remicade®) therapy protects dystrophic skeletal muscle from necrosis. FASEB J 2004; 18: 676-682.
29. Hodgetts S, Radley H, Davies M, Grounds MD. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNF alpha function with etanercept in mdx mice. Neuromuscul Disord 2006; 16: 519-602.
30. Tidball JG, Wehling-Henricks M. Macrophages promote muscle membrane repair and muscle fibre growth and regeneration during modified muscle loading in mice in vivo. J Physiol 2007; 578: 327-336.
31. Wells TNC, Power CA, Shaw JP, Proudfoot AEI. Chemokine blockers-therapeutics in the making? Trends Pharmacol Sci 2006; 27: 41-47.